Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Apellis Pharmaceuticals (NASDAQ:APLS) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 4 | 10 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 5 | 2 | 6 | 0 | 0 |
| 2M Ago | 0 | 1 | 2 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Apellis Pharmaceuticals, revealing an average target of $45.35, a high estimate of $92.00, and a low estimate of $24.00. A 23.06% drop is evident in the current average compared to the previous average price target of $58.94.
Diving into Analyst Ratings: An In-Depth Exploration
A comprehensive examination...
Login or create a forever free account to read this news
Sign up/Log in
